D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization
Open accessPreprint — published as 10.1016/j.chom.2020.11.012 · Paper page
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Summary: The SARS-CoV-2 Spike protein acquired a D614G mutation early in the COVID-19 pandemic that appears to confer on the virus greater infectivity and is now the globally dominant form of the virus. Certain of the current vaccines entering phase 3 trials are based on the original D614 form of Spike with the goal of eliciting protective neutralizing antibodies. To determine whether D614G mediates neutralization-escape that could compromise vaccine efficacy, sera from Spike-immunized mice, nonhuman primates and humans were evaluated for neutralization of pseudoviruses bearing either D614 or G614 Spike on their surface. In all cases, the G614 pseudovirus was moderately more susceptible to neutralization. The G614 pseudovirus also was more susceptible to neutralization by monoclonal antibodies against the receptor binding domain and by convalescent sera from people known to be infected with either the D614 or G614 form of the virus. These results indicate that a gain in infectivity provided by D614G came at the cost of making the virus more vulnerable to neutralizing antibodies, and that the mutation is not expected to be an obstacle for current vaccine development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667
Self-citationAn mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406
Human neutralizing antibodies elicited by SARS-CoV-2 infection
Ju, B., Zhang, Q., Ge, J., Wang, R., Sun, J., Ge, X., Yu, J., Shan, S., Zhou, B., Song, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2380-z · Cited by 1,667
Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen
Pallesen, J., Wang, N., Corbett, K. S., Wrapp, D., Kirchdoerfer, R. N., Turner, H. L., Cottrell, C. A., Becker, M. M., Wang, L., Shi, W., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1707304114 · Cited by 1,073
Rapid Decay of Anti–SARS-CoV-2 Antibodies in Persons with Mild Covid-19
Ibarrondo, F. J., Fulcher, J. A., Goodman-Meza, D., Elliott, J., Hofmann, C., Hausner, M. A., Ferbas, K. G., Tobin, N. H., Aldrovandi, G. M., & Yang, O. O. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2025179 · Cited by 1,021
Pardi, N., Hogan, M. J., Naradikian, M. S., Parkhouse, K., Cain, D. W., Jones, L., Moody, M. A., Verkerke, H. P., Myles, A., Willis, E., et al. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20171450 · Cited by 530
Self-citationFreyn, A. W., Ramos da Silva, J., Rosado, V. C., Bliss, C. M., Pine, M., Mui, B. L., Tam, Y. K., Madden, T. D., de Souza Ferreira, L. C., Weissman, D., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.04.018 · Cited by 299
Self-citation
Research works printed but not linked: 40
- Alameh, M.G. , Weissman, D. , and Pardi, N. (2020). Messenger RNA-Based Vaccines Against Infectious Diseases. Current topics in microbiology and immunology. · DOI · Paper page
- 2019, A Facile Method for the Removal of dsRNA Contaminant from In Vitro-Transcribed mRNA, Molecular therapy Nucleic acids, 15, 26, 10.1016/j.omtn.2019.02.018 · DOI · Paper page
- 10.4103/ijmr.IJMR_1125_20 · DOI
- Brouwer, P.J.M. , Caniels, T.G. , van der Straten, K. , Snitselaar, J.L. , Aldon, Y. , Bangaru, S. , Torres, J.L. , Okba, N.M.A. , Claireaux, M. , Kerster, G., et al. (2020). Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science. · DOI · Paper page
- Chi, X. , Yan, R. , Zhang, J. , Zhang, G. , Zhang, Y. , Hao, M. , Zhang, Z. , Fan, P. , Dong, Y. , Yang, Y. , et al. (2020). A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science. · DOI · Paper page
- Corbett, K.S. , Edwards, D.K. , Leist, S.R. , Abiona, O.M. , Boyoglu-Barnum, S. , Gillespie, R.A. , Himansu, S. , Schafer, A. , Ziwawo, C.T. , DiPiazza, A.T. , et al. (2020). SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature. · DOI · Paper page
- 2020, SARS-CoV-2 genomic surveillance in Taiwan revealed novel ORF8-deletion mutant and clade possibly associated with infections in Middle East, Emerging microbes & infections, 9, 1457, 10.1080/22221751.2020.1782271 · DOI · Paper page
- 10.1016/j.jmb.2004.02.020 · DOI
- Henderson, R. , Edwards, R.J. , Mansouri, K. , Janowska, K. , Stalls, V. , Gobeil, S.M.C. , Kopp, M. , Li, D. , Parks, R. , Hsu, A.L. , et al. (2020). Controlling the SARS-CoV-2 spike glycoprotein conformation. Nat Struct Mol Biol. · DOI · Paper page
- 2020, Evolutionary and structural analyses of SARS-CoV-2 D614G spike protein mutation now documented worldwide, Scientific reports, 10, 14031, 10.1038/s41598-020-70827-z · DOI · Paper page
- Islam, O.K. , Al-Emran, H.M. , Hasan, M.S. , Anwar, A. , Jahid, M.I.K. , and Hossain, M.A. (2020). Emergence of European and North American mutant variants of SARS-CoV-2 in South-East Asia. Transboundary and emerging diseases. · DOI
- 10.1101/2020.03.21.990770 · DOI
- 10.1038/nature17200 · DOI · Paper page
- 2018, Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis, Scientific reports, 8, 15701, 10.1038/s41598-018-34171-7 · DOI · Paper page
- Korber, B. , Fischer, W.M. , Gnanakaran, S. , Yoon, H. , Theiler, J. , Abfalterer, W. , Foley, B. , Giorgi, E.E. , Bhattacharya, T. , Parker, M.D. , et al. (2020a). Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2. bioRxiv: the preprint server for biology 04.29.069054. · DOI
- 10.1016/j.cell.2020.06.043 · DOI · Paper page
- 2020, Variant analysis of SARS-CoV-2 genomes, Bulletin of the World Health Organization, 98, 495, 10.2471/BLT.20.253591 · DOI · Paper page
- Koyama, T. , Weeraratne, D. , Snowdon, J.L. , and Parida, L. (2020b). Emergence of Drift Variants That May Affect COVID-19 Vaccine Development and Antibody Treatment. Pathogens (Basel, Switzerland) 9. · doi:10.20944/preprints202004.0024.v1
- Laczko, D. , Hogan, M.J. , Toulmin, S.A. , Hicks, P. , Lederer, K. , Gaudette, B.T. , Castano, D. , Amanat, F. , Muramatsu, H. , Oguin, T.H. , 3rd, et al. (2020). A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice. Immunity. · DOI · Paper page
- 2013, Influence of cationic lipid composition on uptake and intracellular processing of lipid nanoparticle formulations of siRNA, Nanomedicine: nanotechnology, biology, and medicine, 9, 233, 10.1016/j.nano.2012.05.019 · DOI
- Liu, L. , Wang, P. , Nair, M.S. , Yu, J. , Huang, Y. , Rapp, M.A. , Wang, Q. , Luo, Y. , Sahi, V. , Figueroa, A. , et al. (2020). Potent Neutralizing Monoclonal Antibodies Directed to Multiple Epitopes on the SARS-CoV-2 Spike. bioRxiv: the preprint server for biology.
- 2020, Developing Covid-19 Vaccines at Pandemic Speed, The New England journal of medicine, 382, 1969, 10.1056/NEJMp2005630 · DOI · Paper page
- Mansbach, R.A. , Chakraborty, S. , Nguyen, K. , Montefiori, D. , Korber, B. , and Gnanakaran, S. (2020). The SARS-CoV-2 Spike Variant D614G Favors an Open Conformational State. bioRxiv: the preprint server for biology.
- 10.1097/COH.0000000000000363 · DOI
- 2020, Geographic and Genomic Distribution of SARS-CoV-2 Mutations, Frontiers in microbiology, 11, 1800, 10.3389/fmicb.2020.01800 · DOI · Paper page
- Mulligan, M.J. , Lyke, K.E. , Kitchin, N. , Absalon, J. , Gurtman, A. , Lockhart, S. , Neuzil, K. , Raabe, V. , Bailey, R. , Swanson, K.A. , et al. (2020). Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report. bioRxiv: the preprint server for biology 2020.06.20.159715.
- 10.1126/science.272.5259.263 · DOI · Paper page
- 2015, Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes, Journal of controlled release: official journal of the Controlled Release Society, 217, 345, 10.1016/j.jconrel.2015.08.007 · DOI · Paper page
- 2020, Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody, Nature, 583, 290, 10.1038/s41586-020-2349-y · DOI · Paper page
- Sahin, U. , et al., (2020). Concurrent human antibody and TH1 type T-cell responses elicited by a COVID-19 RNA vaccine. medRxiv: the preprint server for health sciences, https://doi.org/10.1101/2020.1107.1117.20140533. · doi:10.1101/2020.1107.1117.20140533
- 10.1016/bs.mie.2016.04.012 · DOI · Paper page
- Schmidt, F. , Weisblum, Y. , Muecksch, F. , Hoffmann, H.H. , Michailidis, E. , Lorenzi, J.C.C. , Mendoza, P. , Rutkowska, M. , Bednarski, E. , Gaebler, C. , et al. (2020). Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. The Journal of experimental medicine 217. · DOI · Paper page
- Shi, R. , Shan, C. , Duan, X. , Chen, Z. , Liu, P. , Song, J. , Song, T. , Bi, X. , Han, C. , Wu, L. , et al. (2020). A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature. · DOI · Paper page
- 2006, Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants, PLoS medicine, 3, e237, 10.1371/journal.pmed.0030237 · DOI · Paper page
- Wec, A.Z. , Wrapp, D. , Herbert, A.S. , Maurer, D.P. , Haslwanter, D. , Sakharkar, M. , Jangra, R.K. , Dieterle, M.E. , Lilov, A. , Huang, D. , et al. (2020). Broad neutralization of SARS-related viruses by human monoclonal antibodies. Science. · DOI · Paper page
- 10.1126/science.abb2507 · DOI · Paper page
- 10.1126/science.abc2241 · DOI · Paper page
- 10.1126/science.abb7269 · DOI · Paper page
- Yurkovetskiy, L. , Wang, X. , Pascal, K.E. , Tomkins-Tinch, C. , Nyalile, T. , Wang, Y. , Baum, A. , Diehl, W.E. , Dauphin, A. , Carbone, C. , et al. (2020). Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant. bioRxiv: the preprint server for biology July 16, 2020.
- Zhang, L. , Jackson, C.B. , Mou, H. , Ojha, A. , Rangarajan, E.S. , Izard, T. , Farzan, M. , and Choe, H. (2020). The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity. bioRxiv: the preprint server for biology.
Cited by
Greaney, A. J., Starr, T. N., Gilchuk, P., Zost, S. J., Binshtein, E., Loes, A. N., Hilton, S. K., Huddleston, J., Eguia, R., Crawford, K. H. D., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2020.11.007 · Cited by 1,016
SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo
Hou, Y. J., Chiba, S., Halfmann, P., Ehre, C., Kuroda, M., Dinnon, K. H., Leist, S. R., Schäfer, A., Nakajima, N., Takahashi, K., et al. (2020) · Science · doi:10.1126/science.abe8499 · Cited by 900
Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies
Planas, D., Bruel, T., Grzelak, L., Guivel-Benhassine, F., Staropoli, I., Porrot, F., Planchais, C., Buchrieser, J., Rajah, M. M., Bishop, E., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01318-5 · Cited by 697
Structural impact on SARS-CoV-2 spike protein by D614G substitution
Zhang, J., Cai, Y., Xiao, T., Lu, J., Peng, H., Sterling, S. M., Walsh, R. M., Rits-Volloch, S., Zhu, H., Woosley, A. N., et al. (2021) · Science · doi:10.1126/science.abf2303 · Cited by 430
Ella, R., Vadrevu, K. M., Jogdand, H., Prasad, S., Reddy, S., Sarangi, V., Ganneru, B., Sapkal, G., Yadav, P., Abraham, P., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30942-7 · Cited by 424
Metadata
- Authors
- Weissman, D., Alameh, M.-G., de Silva, T., Collini, P., Hornsby, H., Brown, R., LaBranche, C. C., Edwards, R. J., Sutherland, L., Santra, S., Mansouri, K., Gobeil, S., McDanal, C., Pardi, N., Hengartner, N., Lin, P. J. C., Tam, Y., Shaw, P. A., Lewis, M. G., Boesler, C., Şahin, U., Acharya, P., Haynes, B. F., Korber, B., & Montefiori, D. C.
- Venue
- medRxiv
- Publisher
- openRxiv
- Published
- 2020-07-24
- OpenAlex
- W3045042666
- Cited by
- 71
- References
- 7
- Type
- posted content
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.